KAUST DepartmentBiological and Environmental Sciences and Engineering (BESE) Division
Smart Hybrid Materials (SHMs) lab
Physical Sciences and Engineering (PSE) Division
Chemical Science Program
Advanced Membranes and Porous Materials Research Center
MetadataShow full item record
AbstractMulti-drug resistance (MDR) is a trend whereby tumor cells exposed to one cytotoxic agent develop cross-resistance to a range of structurally and functionally unrelated compounds. P -glycoprotein (P -gp) efflux pump is one of the mostly studied drug carrying processes that shuttle the drugs out of tumor cells. Thus, P -gp inhibitors have attracted a lot of attention as they can stop cancer drugs from being pumped out of target cells with the consumption of ATP. Using quantitive structure activity relationship (QSAR), we have successfully synthesized a series of novel P -gp inhibitors. The obtained dihydropyrroloquinoxalines series were fully characterized and then tested against bacterial and tumor assays with over-expressed P -gps. All compounds were bioactive especially compound 1c that had enhanced antibacterial activity. Furthermore, these compounds were utilized as targeting vectors to direct drug delivery vehicles such as silica nanoparticles (SNPs) to cancerous Hela cells with over expressed P -gps. Cell uptake studies showed a successful accumulation of these decorated SNPs in tumor cells compared to undecorated SNPs. The results obtained show that dihydropyrroloquinoxalines constitute a promising drug candidate for targeting cancers with MDR. Copyright © 2013 American Scientific Publishers All rights reserved.
PublisherAmerican Scientific Publishers
- Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
- Authors: Shen J, He Q, Gao Y, Shi J, Li Y
- Issue date: 2011 Oct 5
- Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
- Authors: Koo JS, Choi WC, Rhee YH, Lee HJ, Lee EO, Ahn KS, Bae HS, Ahn KS, Kang JM, Choi SU, Kim MO, Lu J, Kim SH
- Issue date: 2008 Nov 21
- Inhibitors of p-glycoprotein--lead identification and optimisation.
- Authors: Pleban K, Ecker GF
- Issue date: 2005 Feb
- Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
- Authors: Patil Y, Sadhukha T, Ma L, Panyam J
- Issue date: 2009 May 21
- Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
- Authors: Chavanpatil MD, Patil Y, Panyam J
- Issue date: 2006 Aug 31